CPT-Pharmacometrics & Systems Pharmacology

Article	Citations
Issue Information	44
Issue Information	42
Issue Information	41
Correction to Network module‐based drug repositioning for pulmonary arterial hypertension	34
Issue Information	28
Pharmacometric and statistical considerations for dose optimization	28
Prediction of a CLDN18.2 Targeted Antibody Drug Conjugate Pharmacokinetics in Cancer Patients Using PBPK Modeling and Simulation	28
Pharmacokinetics of Intrapartum Benzylpenicillin: Insights Into Candidate Regimens to Prevent Early Onset Neonatal Group B Streptococcus Disease	27
Issue Information	26
A case‐study of model‐informed drug development of a novel PCSK9 anti sense oligonucleotide. Part 1: First time in man to phase II	26
Physiologically‐based pharmacokinetic model of sparsentan to evaluate drug–drug interaction potential	26
Clinical pharmacokinetics of leriglitazone and a translational approach using PBPK modeling to guide the selection of the starting dose in children	26
Development of a physiologically based pharmacokinetic model of fostemsavir and its pivotal application to support dosing in pregnancy	25
Exposure–response modeling for nausea incidence for cotadutide using a Markov modeling approach	25
Evaluation of covariate effects in item response theory models	24
Evaluation of postprandial total triglycerides within the TIGG model for characterizing postprandial response of glucose, insulin, and GLP‐1	24
Increasing application of pediatric physiologically based pharmacokinetic models across academic and industry organizations	24
A systematic efficacy analysis of tuberculosis treatment with BPaL‐containing regimens using a multiscale modeling approach	24
Physiologically‐based pharmacokinetic modeling of pantoprazole to evaluate the role of CYP2C19 genetic variation and obesity in the pediatric population	23
A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP‐1 dual agonist	22
Translational Physiologically Based Pharmacokinetic Modeling to Predict Human Pulmonary Kinetics After Lung Delivery	22
Association between SARS‐CoV‐2 viral kinetics and clinical score evolution in hospitalized patients	21
Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B‐Cell Malignancies	21
Designing phase I oncology dose escalation using dose–exposure–toxicity models as a complementary approach to model‐based dose–toxicity models	21
Step‐by‐step comparison of ordinary differential equation and agent‐based approaches to pharmacokinetic‐pharmacodynamic models	20

Regulatory utility of physiologically based pharmacokinetic modeling for assessing food impact in bioequivalence studies: A workshop summary report	20
Mathematical model of the relationship between pH holding time and erosive esophagitis healing rates	20
Concentration‐QTc and cardiac safety analysis of single and multiple zavegepant nasal spray doses in healthy participants to support approval	20
Genotype, Ethnicity, and Drug–Drug Interaction Modeling as Means of Verifying Transporter Biomarker PBPK Model: The Coproporphyrin‐I Story	19
Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open‐source R package mapbayr	19
A quantitative systems pharmacology approach to support mRNA vaccine development and optimization	18
Exposure–response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors	18
Update to improve reproducibility and interpretability: A response to “Machine Learning for Tumor Growth Inhibition”	18
Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration	18
Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients	18
Interspecies and in vitro‐in vivo scaling for quantitative modeling of whole‐body drug pharmacokinetics in patients: Application to the anticancer drug oxaliplatin	17
Physiologically‐based pharmacokinetic pharmacodynamic parent‐metabolite model of edoxaban to predict drug–drug‐disease interactions: M4 contribution	17
Application of physiologically‐based pharmacokinetic model approach to predict pharmacokinetics and drug–drug interaction of rivaroxaban: A case study of rivaroxaban and carbamazepine	17
Pharmacokinetic/pharmacodynamic analysis of geographic atrophy lesion area in patients receiving pegcetacoplan treatment or sham	16
Quantitative systems toxicology modeling in pharmaceutical research and development: An industry‐wide survey and selected case study examples	16
The population pharmacokinetics of dolutegravir co‐administered with rifampicin in Thai people living with HIV: Assessment of alternative dosing regimens	16
Impact of Mechanistic Modeling and Simulation Methodologies on Product‐Specific Guidance Development for Non‐Orally Administered Drug Products	16
Shap‐Cov: An Explainable Machine Learning Based Workflow for Rapid Covariate Identification in Population Modeling	16
Regulatory utility of physiologically‐based pharmacokinetic modeling to support alternative bioequivalence approaches and risk assessment: A workshop summary report	15
The interaction of core modules as a basis for elucidating network behavior determining Parkinson's disease pathogenesis	15
Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women	15
Issue Information	15
Tutorial on model selection and validation of model input into precision dosing software for model‐informed precision dosing	15
Physiologically based pharmacokinetic modeling of drug–drug interactions between ritonavir‐boosted atazanavir and rifampicin in pregnancy	15
Longitudinal and time‐to‐event modeling for prognostic implications of radical surgery in retroperitoneal sarcoma	14
Population Pharmacokinetics and Transfer of Gabapentin When Used as a Pain Adjunct for Cesarean Deliveries	14
Mechanistic pharmacokinetic–pharmacodynamic modeling and simulations of naloxone auto‐injector 10 mg reversal of opioid‐induced respiratory depression	14
	14
Modeling of Disease Progression of Type 2 Diabetes Using Real‐World Data: Quantifying Competing Risks of Morbidity and Mortality	14
	14
Metaheuristics for pharmacometrics	14
A mechanistic PK/PD model of AZD0171 (anti‐LIF) to support Phase II dose selection	13
Variable or variate? A conundrum in pharmacometrics exposure–response models	13
Population pharmacokinetic and pharmacodynamic model of evogliptin: Severe uremia increases the bioavailability of evogliptin	13
Development and Verification of a Physiologically Based Pharmacokinetic Model of Furmonertinib and Its Main Metabolite for Drug–Drug Interaction Predictions	13
A physiologically‐based pharmacokinetic modeling approach for dosing amiodarone in children on ECMO	13
Population pharmacokinetics and exposure–response modeling for evinacumab in homozygous familial hypercholesterolemia	13
Multivariate modeling of magnetic resonance biomarkers and clinical outcome measures for Duchenne muscular dystrophy clinical trials	13
Precision Medicine in Oncology: Imatinib Dosing in the Obese Cancer Population Using Virtual Clinical Trials	13
Flexible and efficient Bayesian pharmacometrics modeling using Stan and Torsten, Part I	13
Tutorial for Modeling Delays in Biological Systems in the NONMEM Software	13
CYTOCON: The manually curated database of human in vivo cell and molecule concentrations	12
Machine learning algorithms to estimate everolimus exposure trained on simulated and patient pharmacokinetic profiles	12
Physiologically based mechanistic insight into differential risk of valproate hepatotoxicity between children and adults: A focus on ontogeny impact	12
Activity and perspective on quantitative modeling and simulation in Japan: Update from the Pharmaceuticals and Medical Devices Agency	12
Issue Information	12
	12
	12
Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL‐6 levels following administration of the T‐cell bispecific engager g	11
Low‐dimensional neural ordinary differential equations accounting for inter‐individual variability implemented in Monolix and NONMEM	11

Tumor growth inhibition modeling in patients with second line biliary tract cancer and first line non‐small cell lung cancer based on bintrafusp alfa trials	11
Maximum likelihood estimation of renal transporter ontogeny profiles for pediatric PBPK modeling	11
The influence of flip‐flop in population pharmacokinetic analyses	11
Quantitative Systems Toxicology Modeling of Acetaminophen Pharmacokinetics and Hepatic Biomarkers After Overdoses of Extended‐Release and Immediate‐Release Formulations in Adults With Chronic Alcohol	11
	11
Quantitative system pharmacology as a legitimate approach to examine extrapolation strategies used to support pediatric drug development	11
Population pharmacokinetics modeling and exposure‐response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer	11
Type 1 diabetes prevention clinical trial simulator: Case reports of model‐informed drug development tool	11
Elevated acute phase proteins affect pharmacokinetics in COVID‐19 trials: Lessons from the CounterCOVID ‐ imatinib study	10
Population Pharmacokinetic and Exposure‐Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma	10
Multi‐model averaging improves the performance of model‐guided infliximab dosing in patients with inflammatory bowel diseases	10
Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates	10
A Pragmatic Approach to Handling Censored Data Below the Lower Limit of Quantification in Pharmacokinetic Modeling	10
Predicting Residual 21‐Hydroxylase Enzymatic Activity in Pediatric and Adult Congenital Adrenal Hyperplasia Patients: Towards Individualized Therapy	10
A Model‐Based Approach to Evaluate Anti‐Drug Antibody Impact on Drug Exposure With Biologics: A Case Example With the CD3 T‐Cell Bispecific Cibisatamab	10
Regulatory utility of mechanistic modeling to support alternative bioequivalence approaches: A workshop overview	10
Elucidating Contributions of Drug Transporters/Enzyme to Nonlinear Pharmacokinetics of Grazoprevir by PBPK Modeling With a Cluster Gauss–Newton Method	10
PBPK modeling: What is the role of CYP3A4 expression in the gastrointestinal tract to accurately predict first‐pass metabolism?	10
Issue Information	10
Population pharmacokinetic modeling of zavegepant, a calcitonin gene‐related peptide receptor antagonist, in healthy adults and patients with migraine	10
Issue Information	10
Medicines in pregnancy: A clinical pharmacology extrapolation framework to address knowledge gaps	10
Population PK modeling of certolizumab pegol in pregnant women with chronic inflammatory diseases	10
Development of and insights from systems pharmacology models of antibody‐drug conjugates	10
Issue Information	10
Evaluation of the Drug–Drug Interaction Potential of the GlyT1 Inhibitor Iclepertin (BI 425809): A Physiologically Based Pharmacokinetic (PBPK) Modeling Approach	10
Physiologically‐based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B	10
Model‐based meta‐analysis using latent variable modeling to set benchmarks for new treatments of systemic lupus erythematosus	10
Mid‐dosing interval concentration is important for polymyxin B exposure and acute kidney injury in critically ill patients	10
Moving From Point‐Based Analysis to Systems‐Based Modeling: Knowledge Integration to Address Antimicrobial Resistance	9
Semi‐Mechanistic Population Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling of Dupilumab on Pre‐Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)	9
A literature review of drug transport mechanisms during lactation	9
Machine Learning‐Based Model Selection and Averaging Outperform Single‐Model Approaches for a Priori Vancomycin Precision Dosing	9
Issue Information	9
Issue Information	9
Population pharmacokinetic modeling of oral brepocitinib in healthy volunteers and patients with immuno‐inflammatory diseases	9
Item performance of the scale for the assessment and rating of ataxia in rare and ultra‐rare genetic ataxias	9
Evaluation of the drug–drug interaction potential of brigatinib using a physiologically‐based pharmacokinetic modeling approach	9
Elucidating nonlinear pharmacokinetics of telmisartan: Integration of target‐mediated drug disposition and OATP1B3‐mediated hepatic uptake in a physiologically based model	9
Quantitative approaches to drug safety: The 2022 PSP special issue	9
State‐of‐the‐Art on Model‐Informed Drug Development Approaches for Pediatric Rare Diseases	9
Semimechanistic modeling of copeptin and aldosterone kinetics and dynamics in response to rehydration treatment for diabetic ketoacidosis in children	9
Toward improved predictions of pharmacokinetics of transported drugs in hepatic impairment: Insights from the extended clearance model	9
Quantitative systems pharmacology in the age of artificial intelligence	9
Continuous‐Time Markov Population PK/PD Modeling of Longitudinal EASI Categorical Score in Atopic Dermatitis Treated With Rocatinlimab, an Anti‐OX40 Monoclonal Antibody	9
Population pharmacokinetics of intraperitoneal irinotecan and SN‐38 in patients with peritoneal metastases from colorectal origin	9
	9
Physiologically‐based pharmacokinetic modeling for primary metabolites of CYP3A and P‐glycoprotein inhibitors in drug–drug interactions: Should we assume the free drug hypothesis?	8
Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling	8
Predicting the correct dose in children: Role of computational Pediatric Physiological‐based pharmacokinetics modeling tools	8
Development of a cystic fibrosis population model for physiologically based pharmacokinetic models: Is it worth it?	8
	8
Population pharmacokinetics and exposure–clinical outcome relationship of remdesivir major metabolite GS‐441524 in patients with moderate and severe COVID‐19	8
Postmarketing Assessment of Antibody–Drug Conjugates: Proof‐of‐Concept Using Model‐Based Meta‐Analysis and a Clinical Utility Index Approach	8
Issue Information	8
Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non–small cell lung cancer	8
Model‐Based Meta‐Analysis of the Relationship Between Pioglitazone and Histological Outcomes in Metabolic Dysfunction‐Associated Steatohepatitis Patients	8
Supplementing clinical lactation studies with PBPK modeling to inform drug therapy in lactating mothers: Prediction of primaquine exposure as a case example	8
Finding the right hazard function for time‐to‐event modeling: A tutorial and Shiny application	8
Within‐chain parallelization—Giving Stan Jet Fuel for population modeling in pharmacometrics	8
A Pharmacometric Workflow for Resolving Model Instability in Model Use‐Reuse Settings	8
Deep‐NCA: A deep learning methodology for performing noncompartmental analysis of pharmacokinetic data	8
Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID‐19 vaccine Ad26.COV2.S in humans	8
The area under the effect curve as an efficacy determinant for anti‐infectives	8
Development and comparison of model‐integrated evidence approaches for bioequivalence studies with pharmacokinetic end points	8
Population pharmacokinetics of amodiaquine and piperaquine in African pregnant women with uncomplicated Plasmodium falciparum infections	8
Population pharmacokinetic analysis for tisotumab vedotin in patients with locally advanced and/or metastatic solid tumors	8
Population model‐based analysis of the memory B‐cell response following belimumab therapy in the treatment of systemic lupus erythematosus	8
Using mechanistic models to support development of complex generic drug products: European Medicines Agency perspective	8
Translating in vitro CFTR rescue into small molecule correctors for cystic fibrosis using the Library of Integrated Network‐based Cellular Signatures drug discovery platform	8
Applying interpretable machine learning workflow to evaluate exposure–response relationships for large‐molecule oncology drugs	7
Isavuconazole and Calcium Channel Blocker for Invasive Fungal Disease Accompanied With Hypertension: Evidence From the FAERS and PBPK/PD Model	7
	7
Abstracts	7
Pharmacokinetic Model‐Informed Precision Dosing of Natalizumab in Multiple Sclerosis	7
Population PBPK modeling using parametric and nonparametric methods of the Simcyp Simulator, and Bayesian samplers	7
Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis	7
Exposure–response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor	7
	7
A fully automatic tool for development of population pharmacokinetic models	7

Predicting disease activity in patients with multiple sclerosis: An explainable machine‐learning approach in the Mavenclad trials	7
Deep compartment models: A deep learning approach for the reliable prediction of time‐series data in pharmacokinetic modeling	7
Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug	7
Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study	7
Issue Information	7
Model‐informed drug development of voxelotor in sickle cell disease: Population pharmacokinetics in whole blood and plasma	7
A dynamic model of the intestinal epithelium integrates multiple sources of preclinical data and enables clinical translation of drug‐induced toxicity	7
Synthetic Model Combination: A new machine‐learning method for pharmacometric model ensembling	7
Population Pharmacokinetics and Exposure‐Response of Subcutaneous Atezolizumab in Patients With Non‐Small Cell Lung Cancer	6
Mechanistic modeling of ophthalmic, nasal, injectable, and implant generic drug products: A workshop summary report	6
Informing pregnancy dose via target‐mediated drug disposition modeling and simulations for a recombinant human monoclonal antibody	6
In memoriam Lambertus (“Bert”) A. Peletier 29 March 1937–16 December 2023: Furthering quantitative pharmacology through applied mathematics	6
Navigating the landscape of parameter identifiability methods: A workflow recommendation for model development	6
PBPK perspective on alternative CYP3A4 inducers for rifampin	6
Corrigendum to: 2022 WCoP Abstracts	6
Issue Information	6
A Population Pharmacokinetic Model to Inform Extension of the Eteplirsen Dosing Regimen Across the Broad DMD Population	6
Mixed‐effects models and the drug titration paradox	6
A multi‐model approach to predict efficacious clinical dose for an anti‐TGF‐β antibody (GC2008) in the treatment of osteogenesis imperfecta	6
A quantitative systems pharmacology approach to predict the safe‐equivalent dose of doxorubicin in patients with cardiovascular comorbidity	6
Mechanistic modeling of drug products applied to the skin: A workshop summary report	6
Physiologically‐based pharmacokinetic modeling of immunoglobulin and antibody coadministration in patients with primary human immunodeficiency	6
Developmental pharmacokinetics of indomethacin in preterm neonates: Severely decreased drug clearance in the first week of life	6
Skipping a pillar does not make for strong foundations: Pharmacokinetic‐pharmacodynamic reasoning behind the shape of dose–response relationships in oncology	6
	6
Optimizing the design of a pharmacokinetic trial to evaluate the dosing scheme of a novel tuberculosis drug in children living with or without HIV	6
Trapezoid bioequivalence: A rational bioavailability evaluation approach on account of the pharmaceutical‐driven balance of population average and variability	6
Issue Information	6
A continued learning approach for model‐informed precision dosing: Updating models in clinical practice	6
Item Response Modeling and Artificial Neural Network for Differentiation of Parkinson's Patients and Subjects Without Evidence of Dopaminergic Deficit	6
Multistate modeling for survival analysis in critically ill patients treated with meropenem	6
Development of a PBPK model to quantitatively understand absorption and disposition mechanism and support future clinical trials for PB‐201	6
Development of a Joint Tumor Size–Overall Survival Modeling and Simulation Framework Supporting Oncology Development Decision‐Making	6
Population Pharmacokinetic Model of Pegbing in Healthy Subjects and Chronic Hepatitis B Patients	6
Issue Information	6
Growth‐rate model predicts in vivo tumor response from in vitro data	6
Population pharmacokinetic analysis of sparsentan in healthy volunteers and patients with focal segmental glomerulosclerosis	6
Quantitative methods and modeling to assess COVID‐19‐interrupted in vivo pharmacokinetic bioequivalence studies with two reference batches	6
Preclinical side effect prediction through pathway engineering of protein interaction network models	6
Stable warfarin dose prediction in sub‐Saharan African patients: A machine‐learning approach and external validation of a clinical dose–initiation algorithm	6
A framework to guide dose & regimen strategy for clinical drug development	6
Delineating gene–environment effects using virtual twins of patients treated with clozapine	6
Virtual Clinical Trial Reveals Significant Clinical Potential of Targeting Tumor‐Associated Macrophages and Microglia to Treat Glioblastoma	6
Quantitative systems pharmacology model of α‐synuclein pathology in Parkinson's disease‐like mouse for investigation of passive immunotherapy mechanisms	6
	5
Model enhanced reinforcement learning to enable precision dosing: A theoretical case study with dosing of propofol	5
Pharmacokinetic‐pharmacodynamic modelling of the anti‐FcRn monoclonal antibody rozanolixizumab: Translation from preclinical stages to the clinic	5
A network paradigm predicts drug synergistic effects using downstream protein–protein interactions	5
Effect of Cumulative Exposure on the Efficacy of Paroxetine: A Population Pharmacokinetic‐Pharmacodynamic and Machine Learning Analyses	5
Pediatric model‐based dose optimization using a pooled exposure–response safety analysis for nivolumab and nivolumab plus ipilimumab combination in melanoma	5
	5
Introduction of an artificial neural network–based method for concentration‐time predictions	5
A model‐based meta‐analysis of immune‐related adverse events during immune checkpoint inhibitors treatment for NSCLC	5
Biased computation of probability of target attainment for antimicrobial drugs	5
Minimal physiologically‐based hybrid model of pharmacokinetics in pregnant women: Application to antenatal corticosteroids	5
Population pharmacokinetic analysis of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis	5
	5
Evaluation of machine learning methods for covariate data imputation in pharmacometrics	5
To be or not to be, when synthetic data meet clinical pharmacology: A focused study on pharmacogenetics	5
Population pharmacokinetic analysis of zastaprazan (JP‐1366), a novel potassium‐competitive acid blocker, in patients and healthy volunteers	5
Machine learning for tumor growth inhibition: Interpretable predictive models for transparency and reproducibility	5
CKD subpopulations defined by risk‐factors: A longitudinal analysis of electronic health records	5
Applied physiologically‐based pharmacokinetic modeling to assess uridine diphosphate‐glucuronosyltransferase‐mediated drug–drug interactions for Vericiguat	5
Semi‐mechanistic population PK/PD model to aid clinical understanding of myelodysplastic syndromes following treatment with Venetoclax and Azacitidine	5
Application of longitudinal item response theory models to modeling Parkinson’s disease progression	5
PBPK Modeling to Predict Clinical Drug–Drug Interaction and Impact of Hepatic Impairment for an ADC With the Payload Auristatin F‐Hydroxypropylamide	5
Using Pharmacokinetic and Pharmacodynamic Analysis to Optimize the Dosing Regimens of Fanastomig (EMB‐02) in Patients With Advanced Solid Tumors	5
From In Vitro Efficacy to Long‐Term HbA1c Response for GLP‐1R/GlucagonR Agonism Using the 4GI‐HbA1c Systems Model	5
Modeling restoration of gefitinib efficacy by co‐administration of MET inhibitors in an EGFR inhibitor‐resistant NSCLC xenograft model: A tumor‐in‐host DEB‐based approach	5
Consistent methods for fat‐free mass, creatinine clearance, and glomerular filtration rate to describe renal function from neonates to adults	5
Does the choice of applied physiologically‐based pharmacokinetics platform matter? A case study on simvastatin disposition and drug–drug interaction	5
Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID‐19	5
Two new user‐friendly methods to assess pharmacometric parameter identifiability on categorical and continuous scales	5
Development and application of a PBPK modeling strategy to support antimalarial drug development	5
Joint modeling of monocyte HLA‐DR expression trajectories predicts 28‐day mortality in severe SARS‐CoV‐2 patients	5
Computational design of clinical trials using a combination of simulation and the genetic algorithm	5
Hepatic OATP1B zonal distribution: Implications for rifampicin‐mediated drug–drug interactions explored within a PBPK framework	5
Model‐based prediction of progression‐free survival for combination therapies in oncology	5
Physiologically‐based pharmacokinetic modeling of dextromethorphan to investigate interindividual variability within CYP2D6 activity score groups	5
Population pharmacokinetic–pharmacodynamic model of elinzanetant based on integrated clinical phase I and II data	5
Mechanism‐Based Modeling Approaches to Quantify the Effect of Immunogenicity on the Pharmacokinetics of Therapeutic Proteins in Drug Development	4
Development of a Heuristic Machine Analogy Method for Model Simplification With an Application to a Large‐Scale Model of Gi/Gs Signaling	4
LaTeX tutorial for the standardization and automation of population analysis reports	4
Dose optimization of cefazolin in South African children undergoing cardiac surgery with cardiopulmonary bypass	4
Physiologically based pharmacokinetic modeling of imatinib and N‐desmethyl imatinib for drug–drug interaction predictions	4
Mixed effects modeling of radiotherapy in combination with immune checkpoint blockade or inhibitors of theDNAdamage response pathway	4
Learn–confirm in model‐informed drug development: Assessing an immunogenicity quantitative systems pharmacology platform	4
Recent applications of pharmacometrics and systems pharmacology approaches to improve and optimize drug therapy for pregnant and lactating women	4
The Asian Pharmacometrics Network: The historical background, establishment, objectives and roles, and recent activities	4
Construction of a prognostic model based on memory CD4+ T cell–associated genes for lung adenocarcinoma and its applications in immunotherapy	4
Issue Information	4
Dose/exposure–response modeling in dose titration trials: Overcoming the titration paradox	4
Interim analysis, a tool to enhance efficiency of pharmacokinetic studies: Pharmacokinetics of rifampicin in lactating mother–infant pairs	4
Assessing Cytochrome P450 Drug Interaction Risk for Dordaviprone Using Physiologically Based Pharmacokinetic Modeling	4
Mechanistic modeling of generic orally inhaled drug products: A workshop summary report	4